Milestone Pharmaceuticals is trading 5% down at $1.02, most likely reflecting broader risk-off conditions as Treasury yields rise and major U.S. indexes weaken.
- The decline reverses the August 19 close of $1.08.
- No negative company-specific announcement was identified for August 20, 2026; Cantor Fitzgerald initiated coverage with an Overweight rating and a $3 price target.
- Healthcare stocks were rallying, so the move does not appear sector-driven.